Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000666894 | SCV000791263 | uncertain significance | Familial dysautonomia | 2017-05-15 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001041168 | SCV001204769 | uncertain significance | not provided | 2022-10-25 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 1133 of the ELP1 protein (p.Arg1133Cys). This variant is present in population databases (rs372499865, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with ELP1-related conditions. ClinVar contains an entry for this variant (Variation ID: 551755). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ELP1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004026094 | SCV003742013 | uncertain significance | not specified | 2022-10-05 | criteria provided, single submitter | clinical testing | The c.3397C>T (p.R1133C) alteration is located in exon 32 (coding exon 31) of the IKBKAP gene. This alteration results from a C to T substitution at nucleotide position 3397, causing the arginine (R) at amino acid position 1133 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000666894 | SCV001452823 | uncertain significance | Familial dysautonomia | 2020-09-16 | no assertion criteria provided | clinical testing |